That sounds about right imo. $750 mil would be a 10 bagger from here, $525 mil a 7 bagger. That shows just how undervalued the stock is, even after the recent rebound. The key to stopping C. Dif is for the patient to maintain and restore their normal gut microbiome, which is what occurs with ACXP's approach. Vancomycin kills the C. Dif, but simultaneously wipes out the entire normal gut flora, leading to reinfection / recurrence. There are never any guarantees in biotech, but ACXP looks like the best odds you are likely to see in the sector, imo.
---
News 
Market Data 
Discover 
AI
